GlassScriptPhysician profile
Irwin S Goldstein
NPI 1972603694
$3,301.77
in general payments reported to CMS, 2019-2025
28 companies · $486 in 2025
The $486 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $465 · 2021: $443 · 2022: $403 · 2023: $454 · 2024: $511 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $715.69 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $524.16 | 2019-2025 | |
| Janssen Biotech, INC. | $467.89 | 2020-2024 | Erleada, Akeega |
| Abbvie INC. | $317.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $198.67 | 2020-2025 | Lynparza, Keytruda, Lenvima |
| Urovant Sciences INC | $125.00 | 2022 | |
| Coloplast Corp | $109.71 | 2019-2025 | |
| Convatec INC. | $96.28 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $95.76 | 2023-2024 | Gemtesa |
| Axonics, INC. | $78.15 | 2024 | Axonics |
| Urogen Pharma, INC. | $63.48 | 2022-2024 | Jelmyto |
| Astellas Pharma Global Development | $62.60 | 2025 | Veozah |
| Antares Pharma, INC. | $60.75 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $50.44 | 2023-2024 | Prolaris |
| Novartis Pharmaceuticals Corporation | $43.55 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $43.53 | 2021-2023 | Interstim |
| Pfizer INC. | $32.77 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $31.54 | 2019-2020 | |
| Amgen INC. | $27.14 | 2021 | |
| Boston Scientific Corporation | $22.30 | 2025 | Axonics |
| Teleflex LLC | $20.50 | 2025 | Barrigel |
| Tolmar Pharmaceuticals, INC. | $18.26 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.19 | 2019 | |
| Dendreon Pharmaceuticals LLC | $17.94 | 2019 | |
| Calyxo, INC. | $17.14 | 2025 | Cvac Aspiration System |
| Olympus America INC. | $16.60 | 2025 | Bovie |
| Photocure INC | $14.23 | 2024 | Cysview |
| Allergan, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irwin Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.